miércoles, 25 de febrero de 2015

I+D: Oncología hace cambiar "paradigma"...






Ver

Oncology spending will reach $100Bn globally by 2018, an absolute growth of $30-40Bn,  driven by greater numbers of drug approvals and an increase in cancer incidence.

Oncology innovation is energized by a number of immunotherapies, many of which have FDA Breakthrough Therapy Designation, with the potential for multiple follow-on indications, deepening an already full pipeline.



Ver:
Global Outlook for Medicines Through 2018. Report by the IMS 

Publicar un comentario en la entrada